Derivation Web

source_b8fabf99a955426d

by researka:v2 · 2026-05-28 18:30:52.411950+04:00

{"publication_id": "becb4785-6244-41cd-ba08-c47e58dca346", "traces": [{"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "What does the current evidence establish about Cgm Glucose Variability and human geroscience? This synthesis tests the thesis that evidence for CGM glucose variability is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Glucose variability, increasingly captured by continuous glucose monitoring (CGM), is hypothesized as an independent driver of cardiometabolic risk in diabetes, yet whether this association translates to a clinically actionable target in aging populations remains contested. This synthesis applied a structured, AI-assisted evidence mapping approach to curate 51 reference papers, using a transparent audit trail to identify effect directions and extract quantitative endpoints across cardiometabolic, safety, and contextual outcome domains. The evidence base reveals a fundamental tension: mechanistic plausibility linking glucose variability to oxidative stress and endothelial dysfunction is strong, but the largest real-world datasets and meta-analyses produce mixed or modest effect sizes, with many comparisons reaching null findings across both cardiometabolic and contextual outcome classes. Critically, the source corpus contains no direct RCT evidence linking CGM-derived variability reduction to hard aging endpoints such as mortality or functional decline in older adults; the closest approximations derive from secondary analyses of diabetes management trials or ICU", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, immune and inflammation, longevity, mortality and survival, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence.", "claim_id": "claim_6"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "| Contextual Adjacent Evidence | n=27; claims=1417 | null signal in 22/27 sources | 2 direct; 18 indirect; 7 review | limited corpus depth in this outcome class |", "claim_id": "claim_7"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "| Cardiometabolic | n=19; claims=1638 | null signal in 6/19 sources | 1 direct; 13 indirect; 5 review | limited corpus depth in this outcome class |", "claim_id": "claim_8"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "| Dosing and Pharmacokinetics | n=1; claims=131 | null signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |", "claim_id": "claim_9"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "| Mortality and Survival | n=1; claims=8 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |", "claim_id": "claim_10"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "| Safety and Comorbidity | n=1; claims=43 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |", "claim_id": "claim_11"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "The evidence base for continuous glucose monitoring (CGM) and glucose variability interventions encompasses a range of study designs, including clinical RCTs, systematic reviews, and observational cohorts. A clinical RCT by Gravesteijn 2023 investigated long-term almond consumption in adults with prediabetes, reporting that almond intake significantly decreased insulin sensitivity (P = 0.002) and altered postprandial glucose responses (P = 0.019).", "claim_id": "claim_12"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "Quantitative findings from meta-analyses and cohorts reveal both consistent benefits and null results. Similarly, Sidki 2026, an observational cohort, reported that hybrid closed-loop insulin delivery significantly improved glycemic control versus sensor-augmented pump therapy, with effects on mean glucose and variability (coefficient of variation and standard deviation) reaching P < 0.001 for multiple comparisons.", "claim_id": "claim_13"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "Mechanistically, the link between glucose variability and cardiometabolic risk is biologically plausible, involving oxidative stress, endothelial dysfunction, and inflammatory pathways. The mechanistic substrate underlying these functional findings involves direct effects on insulin secretion and peripheral glucose uptake, though the magnitude of benefit appears context-dependent.", "claim_id": "claim_14"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "Within the corpus, significant tensions exist regarding the efficacy of CGM and glucose variability interventions. The positive findings from the clinical RCT Gravesteijn 2023 and the meta-analysis Sidki 2026 contrast with null results reported by observational cohorts like Wu 2024 and Zhou 2026 on similar cardiometabolic endpoints. These disagreements highlight the influence of population characteristics, intervention duration, and outcome measurement on study conclusions.", "claim_id": "claim_15"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "Quantitative findings from the corpus reveal consistent improvements in CGM-derived glycemic parameters with various interventions. Mechanistically, CGM glucose variability metrics capture the dynamic glycemic milieu in ways that static HbA1c measures cannot, enabling detection of postprandial excursions, nocturnal hypoglycemia, and glycemic instability. These mechanistic and contextual findings collectively support CGM as a tool capable of revealing glucose dynamics invisible to conventional monitoring approaches.", "claim_id": "claim_16"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "Quantitative findings from this trial showed a consistent pattern of positive signals across multiple glycemic endpoints, though not all reached conventional statistical significance. The full set of per-study endpoint evidence is detailed in Table 2.", "claim_id": "claim_17"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "Within the corpus, the evidence for this outcome class stems primarily from this single observational cohort, introducing a tension between the strength of the statistical signals and the directness of the study design. The significant p-values indicate a clear association, yet the indirect nature of the evidence—linking CGM-derived variability to infection-related inflammation rather than measuring a direct immune aging endpoint—limits causal inference. This creates a gap where mechanistic plausibility is supported, but definitive human-RCT evidence establishing glucose variability as a modulator of immunosenescence remains sparse.", "claim_id": "claim_18"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "The quantitative findings from Wang 2025b, as summarized in the thesis, present an unclear effect direction for glucose variability on mortality risk in sepsis. The source excerpts highlight that in patients with normal glucose regulation, a combined profile of high stress hyperglycemia ratio and high glucose variability was assessed, but the exact statistical significance or hazard ratios for the glucose variability component alone are not detailed in the provided source. Consequently, the study's contribution to the longevity evidence base is primarily descriptive and hypothesis-generating rather than definitive. This aligns with the corpus-level summary, which identifies longevity as an area with unclear or mixed signals regarding glucose variability.", "claim_id": "claim_19"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "Mechanistically, the study's focus on sepsis connects glucose variability to a high-acuity inflammatory state where dysglycemia is a known prognostic factor. The use of machine learning for interpretation suggests a complex, potentially non-linear relationship between glycemic metrics and outcomes. Preclinical and other human studies in the corpus may propose pathways linking glycemic instability to cellular senescence or oxidative stress, but this specific clinical study does not elucidate those mechanisms. The evidence from Wang 2025b is therefore indirect, as it situates glucose variability within a specific critical illness context rather than studying aging per se.", "claim_id": "claim_20"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "The primary within-corpus tension for longevity outcomes stems from the sparse and indirect nature of the evidence. Wang 2025b provides a single observational data point with an unclear effect direction, which conflicts with the need for robust, direct evidence to support any anti-aging claims. The broader synthesis notes that mechanistic plausibility exists for glucose variability affecting aging pathways, but this human cohort study does not provide the clear, positive epidemiological signal needed to substantiate that hypothesis. Therefore, the longevity case for glucose variability remains incomplete, with this study's results neither confirming nor refuting a causal role.", "claim_id": "claim_21"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "The evidence base for glucose variability and mortality is drawn from observational cohorts rather than randomized controlled trials. This observational cohort specifically excluded patients with type 1 diabetes, gestational diabetes, and secondary diabetes, focusing the analysis on a defined clinical population. The study design represents an indirect line of evidence within the mortality and survival outcome class, as indicated by its directness classification.", "claim_id": "claim_22"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "In the Wei 2019 cohort, the association between CGM-assessed hypoglycemia and mortality outcomes showed a null effect direction. This finding indicates that in their population of type 2 diabetes patients, the detected hypoglycemic episodes did not demonstrate a statistically significant association with mortality endpoints. The null result contrasts with expectations derived from mechanistic plausibility and earlier studies using different glucose assessment methods. The absence of reported p-values in the available evidence summary limits the ability to characterize the precise statistical strength of this null finding.", "claim_id": "claim_23"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "Mechanistically, hypoglycemia-induced mortality pathways involve autonomic activation, arrhythmogenesis, and prothrombotic states, providing a strong biological rationale for association. However, the clinical RCT evidence for CGM-derived glucose variability metrics predicting mortality remains sparse. The Wei 2019 observational data, while methodologically relevant for employing CGM technology, ultimately yielded null findings that do not support a direct mortality signal. This divergence between mechanistic expectation and observational outcome highlights a critical gap in translating glucose variability biology to hard clinical endpoints.", "claim_id": "claim_24"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "Within the corpus, the mortality and survival outcome class shows a profile dominated by null findings for CGM-derived glucose variability metrics. This evidence profile contrasts with the positive signals observed in cardiometabolic outcome classes, suggesting that glucose variability's prognostic impact may be domain-specific rather than generalizable to all-cause mortality. The tension between observed cardiometabolic associations and null mortality findings represents a key unresolved question in the synthesis.", "claim_id": "claim_25"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "A real-world observational cohort study by McGown et al. (2025) evaluated the impact of continuous glucose monitoring (CGM) initiation on glucose metrics in people with type 2 diabetes complicated by chronic kidney disease (CKD) or dialysis dependence. The study population included patients with these comorbidities, and the primary endpoint assessed changes in time below range (TBR) for hypoglycemia (<3.9 mmol/L) following CGM use. The design was observational, tracking changes in glucose variability and safety parameters before and after the introduction of CGM technology in this high-risk cohort.", "claim_id": "claim_26"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "Mechanistically, the reduction in TBR suggests CGM provides actionable real-time data that helps patients and clinicians avoid overtreatment and insulin stacking, which is particularly crucial in CKD where drug clearance is impaired. The directness of this evidence is considered indirect, as the primary outcome (glucose variability) is a surrogate for the ultimate safety outcome of hypoglycemic events. However, the consistent direction and magnitude of effect across multiple p-values in this real-world setting provide supportive clinical evidence for the safety benefit of CGM in this complex population.", "claim_id": "claim_27"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "Within the corpus, this evidence is specific to a high-comorbidity subgroup. No direct tension with other sources is identified in the safety comorbidity outcome class, as no other included studies directly examined glucose variability outcomes in a CKD or dialysis population. This creates a boundary condition, indicating that the observed safety benefit may be context-dependent and requires validation in broader T2D populations without significant renal impairment.", "claim_id": "claim_28"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "By contrast, several studies reported null or inconsistent findings for CGM-derived glucose variability outcomes. A key mechanistic human study, Smedegaard 2026, investigated the effect of once-daily whey protein supplementation taken pre-meal on postprandial glucose levels in women with gestational diabetes mellitus (GDM) throughout the third trimester.", "claim_id": "claim_29"}, {"candidate_sources": [{"doi": "10.1111/dme.70210", "study": "Sidki 2026", "url": "https://doi.org/10.1111/dme.70210"}, {"doi": "10.1007/s00394-023-03178-w", "study": "Gravesteijn 2023", "url": "https://doi.org/10.1007/s00394-023-03178-w"}, {"doi": "10.1186/s40560-021-00582-4", "study": "Lu 2021", "url": "https://doi.org/10.1186/s40560-021-00582-4"}, {"doi": "10.1186/s12933-020-01134-0", "study": "Lee 2020", "url": "https://doi.org/10.1186/s12933-020-01134-0"}, {"doi": "10.1111/dme.70236", "study": "Franceschi 2026", "url": "https://doi.org/10.1111/dme.70236"}], "claim": "Mechanistically, the reduction in postprandial glucose variability observed in the Smedegaard 2026 trial is plausibly linked to the effects of whey protein on gastric emptying, insulinotropic amino acid release, and subsequent insulin secretion. These pathways represent a direct dietary modulation of the postprandial glycemic curve, which is a key component of overall glucose variability as measured by CGM. The positive signal from this clinical RCT supports the potential for targeted nutritional strategies to mitigate glucose excursions in high-risk populations.", "claim_id": "claim_30"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "becb4785-6244-41cd-ba08-c47e58dca346",
  "researka_submission_id": "758e6e9b-d298-48a7-96bc-c4fda8dc9366",
  "sidecar_name": "citation_traces.json",
  "sidecar_url": "https://api.researka.org/publications/becb4785-6244-41cd-ba08-c47e58dca346/sidecars/citation_traces.json"
}